CongoTuberculosis profile
Population  2015 4.6 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.3 (1.3–3.5) 49 (29–75)
Mortality (HIV+TB only) 2.4 (2–2.9) 53 (44–63)
Incidence  (includes HIV+TB) 18 (11–25) 379 (246–542)
Incidence (HIV+TB only) 6.4 (3.9–9.5) 138 (84–205)
Incidence (MDR/RR-TB)** 0.67 (0.29–1) 15 (6.3–22)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 1 (0.5–1.5) 6.9 (3.6–10) 7.9 (4.1–12)
Males 0.92 (0.55–1.3) 8.7 (6–11) 9.6 (6.5–13)
Total 1.9 (1.3–2.6) 16 (12–19) 18 (11–25)
TB case notifications, 2015  
Total cases notified 10 119
Total new and relapse 9 937
          - % tested with rapid diagnostics at time of diagnosis 3%
          - % with known HIV status 13%
          - % pulmonary 75%
          - % bacteriologically confirmed among pulmonary 51%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 57% (40–88)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.28 (0.17–0.44)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 479 38%
          - on antiretroviral therapy 164 34%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  300
(160–430)
Estimated % of TB cases with MDR/RR-TB 3.2% (1.4–5) 14% (6.9–21)  
% notified tested for rifampicin resistance   2015% 9 469
MDR/RR-TB cases tested for resistance to second-line drugs   5
Laboratory-confirmed cases MDR/RR-TB: 41, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 13, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 69% 4 108
Previously treated cases, excluding relapse, registered in 2014 94% 182
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 3.8
Funding source: 12% domestic, 68% international, 20% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data